Cosyntropin
Highest phase reached
Approved
Drug type
Protein
First approval year
1970
- First approval year
- 1970
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Protein
- Drug name
- Cosyntropin
- Molecular weight
- 2,933.49
- Structure (SMILES)
- CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)O)C(C)C)C(C)C)C(C)C
- cortrosyn
- Cortrosyn
- cosyntropin
- Cosyntropin
- synacthen
- Synacthen
- synacthen depot
- Synacthen depot
- 1 mcg synacthen
- adrenocorticotropic hormone fragment 1 24 human rat
- ADRENOCORTICOTROPIC HORMONE FRAGMENT 1-24 HUMAN, RAT
- corticotropin tetracosapeptide
- Corticotropin tetracosapeptide
- cortrosyn
- Cortrosyn
- cosyntropin
- Cosyntropin
- Cosyntropin (Group 3)
- COSYNTROPIN [HSDB]
- COSYNTROPIN [MI]
- COSYNTROPIN [ORANGE BOOK]
- COSYNTROPIN [USAN]
- COSYNTROPIN [USP MONOGRAPH]
- COSYNTROPIN [VANDF]
- cosyntropin acetate
- Cosyntropin acetate
- cosyntropin hexaacetate
- Cosyntropin hexaacetate
- cosyntropin hsdb
- cosyntropin mi
- cosyntropin orange book
- cosyntropin usan
- cosyntropin usp monograph
And 31 more, listed on the interactive page.
- ATC classification codes
- H01AA02
Sources for recorded values
- CAS registry numbers
- 16960-16-0
- ChEMBL ID
- CHEMBL2103784
- InChIKey
- ZOEFCCMDUURGSE-SQKVDDBVSA-N
- RxNorm IDs (RxCUI)
- 2890
- FDA ingredient codes (UNII)
- 72YY86EA29
- 16133751
- 16133802
- 60210072
- 129627786
- Applicant
- AMPHASTAR PHARMS INC
- Approval date
- 22 Apr 1970
- Application number
- NDA016750
- Patents
- 0
- Designations
- 2
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Pharmacology name
- cosyntropin
- Type
- Peptide
- Drug name stem
- -pin; -trop-
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Parenteral
- Action
- Agonist
- Action type
- Agonist
- Target
- MC2 receptor
- Gene symbol
- MC2R
- Protein identifier
- Q01718
- Primary target
- Yes
- Mechanism
- Melanocortin receptor 2 agonist
- Action type
- Agonist
- Target
- Adrenocorticotropic hormone receptor
- Protein identifier
- Q01718
Open Targets mechanisms
- Mechanism
- Melanocortin receptor 2 agonist
- Action type
- Agonist
- Target
- Adrenocorticotropic hormone receptor
DrugCentral mechanisms
- Action type
- Agonist
- Gene symbol
- MC2R
- Protein identifier
- Q01718
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Hypertension
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0000537
- Subject identifier
- D006973
- Condition
- Glomerulonephritis, Membranous
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004254
- Subject identifier
- D015433
- Condition
- Adrenal Gland Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0005539
- Subject identifier
- D000307
- Condition
- Spasms, Infantile
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0100062
- Subject identifier
- D013036
- Condition identifier
- EFO_0000537
- Condition identifier
- EFO_0004254
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005539
- Highest recorded phase
- 1
- Condition identifier
- EFO_0009491
- Condition identifier
- EFO_0009505
- Condition identifier
- MONDO_0000004
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005376
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0018097
- Highest recorded phase
- 3
- Event
- allergic granulomatous angiitis
- Reports
- 2
- Reporting signal score
- 7.95966
- Event
- cerebral disorder
- Reports
- 4
- Reporting signal score
- 15.7708
- Event
- choreoathetosis
- Reports
- 2
- Reporting signal score
- 8.8473
- Event
- cushing's syndrome
- Reports
- 3
- Reporting signal score
- 10.0431
- Event
- diabetic ketoacidosis
- Reports
- 4
- Reporting signal score
- 7.8533
- Event
- drug resistance
- Reports
- 6
- Reporting signal score
- 14.3964
- Event
- foetal growth restriction
- Reports
- 13
- Reporting signal score
- 58.7777
- Event
- hypoglycaemia
- Reports
- 12
- Reporting signal score
- 30.3785
- Event
- hypoglycaemia neonatal
- Reports
- 2
- Reporting signal score
- 7.68796
- Event
- hypokalaemia
- Reports
- 6
- Reporting signal score
- 10.8646
- Event
- hypothalamic pituitary adrenal axis suppression
- Reports
- 6
- Reporting signal score
- 39.7363
- Event
- infantile spasms
- Reports
- 2
- Reporting signal score
- 9.88244
- Event
- irritability
- Reports
- 6
- Reporting signal score
- 11.476
- Event
- lung consolidation
- Reports
- 2
- Reporting signal score
- 7.25483
- Event
- multiple-drug resistance
- Reports
- 6
- Reporting signal score
- 27.7423
- Event
- nuclear magnetic resonance imaging brain abnormal
- Reports
- 2
- Reporting signal score
- 7.76908
- Event
- poor sucking reflex
- Reports
- 2
- Reporting signal score
- 10.1926
- Event
- rhinovirus infection
- Reports
- 2
- Reporting signal score
- 7.20008
- Event
- seizure cluster
- Reports
- 3
- Reporting signal score
- 17.453
- Event
- status epilepticus
- Reports
- 3
- Reporting signal score
- 7.20045
- Event
- vaccination failure
- Reports
- 2
- Reporting signal score
- 9.986
- NCT00694863
- NCT01839812
- NCT03347526
- NCT04546126
- Dose
- 0.25 mg
- Route
- Intravenous or intramuscular
- How often
- Once
Conditions of use
- Discard unused portion
- Calculated partition coefficient (XLogP)
- -7.9
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Heavy atoms
- 208
- Molecular formula
- C136H210N40O31S
- Monoisotopic mass
- 2931.5806412
- Natural product
- Yes
- 0404-9839
- 0548-5900
- 0781-3440
- 51662-1567
- 71872-7313
- 71872-7318
- Recorded assays
- 30
- Active assays
- 0
Related records
Trials (48)
- A Clinical Study on the Treatment of Wilson Disease With ATP7B mRNA/LNP (DSL101)
- A Dose-response Study of Tranexamic Acid in Total Hip Arthroplasty
- A Novel Approach to Infantile Spasms
- A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™
- A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate
- A Phase I/II Study of BMN053 in Subjects With Duchenne Muscular Dystrophy (DMD)
- A Phase II Clinical Trial of the Safety and Efficacy of SAL056 at Different Doses and Dosing Regimens
- A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)
- A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
- A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
- Adrenal Responsiveness During the Perioperative Period in Children Undergoing Congenital Cardiac Surgery
- Adrenocorticotropic Hormone Stimulation in Postural Orthostatic Tachycardia Syndrome (POTS)
- An 8-week Full Face HUT Clinical Trial for HydroBoost (2.0/3.0)
- An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis
- Bio-Manguinhos/Fiocruz COVID-19 (mRNA) Vaccine Booster
- Cardioprotective Effect of Melatonin Versus Vitamin D in Breast Cancer Patients Receiving Doxorubicin
- Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age
- Comparison of 5 Buffering Agents on Changes in Salivary pH in Individuals Previously Exposed to a Test Carbonated Drink
- Comparison of 5 Buffering Agents on Changes in Salivary pH in Individuals Previously Exposed to a Test Fruit Juice
- Comparison of Intramuscular and Intravenous ACTH Stimulation Test in Normal Volunteers
In development for (4)
- Adrenal gland disorder Phase 1
- Genetic developmental and epileptic encephalopathy Phase 3
- Hypertensive disorder Early phase 1
- Membranous glomerulonephritis Phase 2
Other linked conditions (1)
- Adrenocortical insufficiency
Targets (1)
- MC2R Melanocortin receptor 2 agonist